Search - tctmd.com

Displaying 1 - 20 of 21

Sort: Relevancy | Date

Top News in Heart Failure: 2018

News Features

Top News in Heart Failure: 2018

December 28, 2018

EMPA-HEART Offers Mechanistic Clues for Empagliflozin’s Cardiac Benefits

News Conference News AHA 2018

EMPA-HEART Offers Mechanistic Clues for Empagliflozin’s Cardiac Benefits

Michael O'Riordan

November 16, 2018

Canakinumab Reduces Heart-Failure Hospitalizations Among Responders: CANTOS Subanalysis

News Conference News AHA 2018

Canakinumab Reduces Heart-Failure Hospitalizations Among Responders: CANTOS Subanalysis

November 13, 2018

DECLARE-TIMI 58 Supports HF Benefit of SGLT2 Inhibitors

News Conference News AHA 2018

DECLARE-TIMI 58 Supports HF Benefit of SGLT2 Inhibitors

November 10, 2018

AHA 2018: New Cholesterol Guidelines, Fish Oil, Diabetes Meds, and Inflammation Blow Into the Windy City

News Conference News AHA 2018

AHA 2018: New Cholesterol Guidelines, Fish Oil, Diabetes Meds, and Inflammation Blow Into the Windy City

November 05, 2018

TCTMD’s Top 10 Most Popular Stories for September 2018

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for September 2018

October 02, 2018

Dapagliflozin Gets Partial Win in DECLARE-TIMI 58

News Daily News

Dapagliflozin Gets Partial Win in DECLARE-TIMI 58

October 02, 2018

State-of-the-Art: Medical Therapies for CHF (With a Focus on Diabetes)

Presentation TCT 2018

State-of-the-Art: Medical Therapies for CHF (With a Focus on Diabetes)

Presenter: James E. Udelson, Clyde W. Yancy, Ileana L. Pina

September 22, 2018

My Takeaways From ESC 2018: Good or Bad, the Luxury of New Data Begets Cries for More

News Conference News ESC 2018

My Takeaways From ESC 2018: Good or Bad, the Luxury of New Data Begets Cries for More

September 14, 2018

ESC 2018: Trimming DAPT, New NOAC Niches, Aspirin Scrutiny for Primary Prevention, and More

News Conference News ESC 2018

ESC 2018: Trimming DAPT, New NOAC Niches, Aspirin Scrutiny for Primary Prevention, and More

August 20, 2018

SGLT2 Inhibitors Work in Type 2 Diabetes Across Levels of CV Risk, Renal Function

News Daily News

SGLT2 Inhibitors Work in Type 2 Diabetes Across Levels of CV Risk, Renal Function

July 02, 2018

NSAIDs Account for Large Part of Osteoarthritis-CVD Link, Study Suggests

News Daily News

NSAIDs Account for Large Part of Osteoarthritis-CVD Link, Study Suggests

June 21, 2018

Heart Transplants From Overdose Deaths Are Soaring, With Promising Results

News Daily News

Heart Transplants From Overdose Deaths Are Soaring, With Promising Results

Yael L. Maxwell

April 17, 2018

Rates of Heart Failure After Acute MI Declining, Statewide Analysis Shows

News Daily News

Rates of Heart Failure After Acute MI Declining, Statewide Analysis Shows

Michael O'Riordan

April 05, 2018

Time for Guidelines to Recommend ARBs Over ACE Inhibitors?

News Daily News

Time for Guidelines to Recommend ARBs Over ACE Inhibitors?

March 29, 2018

Urgent/Emergent TAVR: Risky but Rewarding, TVT Registry Data Hint

News Conference News ACC 2018

Urgent/Emergent TAVR: Risky but Rewarding, TVT Registry Data Hint

March 19, 2018

CANVAS Analysis Provides Heart Failure Reassurances for Canagliflozin

News Conference News

CANVAS Analysis Provides Heart Failure Reassurances for Canagliflozin

Michael O'Riordan

March 16, 2018

Obesity Robs People of CVD-Free Years and Ups the Risk of Dying Young

News Daily News

Obesity Robs People of CVD-Free Years and Ups the Risk of Dying Young

Michael O'Riordan

March 02, 2018

LV Diastolic Dysfunction Linked With Higher Mortality Post-TAVR

News Daily News

LV Diastolic Dysfunction Linked With Higher Mortality Post-TAVR

Yael L. Maxwell

March 01, 2018

Diabetes, Multivessel CAD, and LV Dysfunction? Registry Analysis Gives CABG the Edge Over PCI

News Daily News

Diabetes, Multivessel CAD, and LV Dysfunction? Registry Analysis Gives CABG the Edge Over PCI

Michael O'Riordan

February 20, 2018

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.